Scholarlink

Objective <p>To assess the burden of systemic lupus erythematosus (SLE) from the perspective of patients in Latin America (LATAM) in 2024.</p> Methods <p>During May 2024, as part of International SLE Awareness Day, the <i>Grupo Latinoamericano de Estudio del Lupus</i> (GLADEL) disseminated an anonymous, bilingual (Spanish/Portuguese) online survey to patients with SLE. The survey, developed by Lupus Europe, was distributed through physicians and patient associations across LATAM and explored sociodemographic characteristics, disease features, treatments, and the impact on daily life.</p> Results <p>A total of 1991 responses from 21 Latin American countries were analyzed (Argentina, Brazil, the Dominican Republic, Chile, and Peru contributing the highest numbers). Most respondents were women (95.2%), with a mean age of 38.6&#xa0;years (SD 11.6). Overall, 52.1% were married or partnered, 34.0% had completed secondary/vocational education, and 38.8% were employed. Regarding ethnicity, 25.5% identified as Caucasian and 34.4% as Mestizo. A prior alternative diagnosis was reported by 59.7%, with a mean age at diagnosis of 28.8&#xa0;years (SD 10.6) and a median delay of 1&#xa0;year (IQR 0–2). The most frequently affected organs were joints (71.4%), skin (47.4%), and kidneys (37.5%). Emotional and sexual life were negatively affected in 43.2%, and 62.1% reported impacts on education or career. Anxiety and/or depression were reported by 60%. Antimalarials, corticosteroids, immunosuppressives, and biologics were used by 80.9%, 55.7%, 59.9%, and 11.1%, respectively. Notably, 67.7% perceived their disease as under control.</p> Conclusion <p>Understanding patient perspectives is essential to evaluate the burden of SLE, and incorporating patient-reported experiences into decision-making should be prioritized.<Table Float="No" ID="Taba"> <tgroup cols="2"> <colspec align="left" colname="c1" colnum="1" /> <colspec align="left" colname="c2" colnum="2" /> <tbody> <row> <entry align="left" nameend="c2" namest="c1"> <p><b>Key Points</b></p> <p>• Nearly 60% of patients experienced a misdiagnosis, with a median 1-year diagnostic delay.</p> <p>• High psychosocial burden, including education/career disruption and anxiety/depression.High psychosocial burden, including education/career disruption and anxiety/depression.</p> <p>• Conventional therapies are widely used; biologics remain underutilized.</p> <p>• Two-thirds of patients perceived their disease as controlled.</p> </entry> </row> </tbody> </tgroup> </Table></p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Living with systemic lupus erythematosus in 2024: Latin American experience based on a patient survey

  • 期刊论文

  • 发表日期：

    2025年12月5日

查看全文
  • Rosana Quintana,
  • Veronica Bellomio,
  • Manuel Ugarte-Gil,
  • Diana Fernandez,
  • Romina Nieto,
  • Marina Scolnik,
  • Carmen Funes Soaje,
  • Paula Alba,
  • Verónica Saurit,
  • Mercedes Garcia,
  • Guillermo Berbotto,
  • Eduardo Kerzberg,
  • Graciela Gómez,
  • Cecilia Pisoni,
  • Nilzio Antonio da Silva,
  • Luciana Parente,
  • Odirlei Andre Monticielo,
  • Henrique Ataide Mariz,
  • Francinne Machado Ribeiro,
  • Eduardo F. Borba,
  • Edgard Torres Dos Reis Neto,
  • Iris Guerra Herrera,
  • Loreto Massardo,
  • Gustavo Aroca Martinez,
  • Carlos Alberto Cañas Dávila,
  • Gerardo Quintana López,
  • Mario Moreno,
  • Miguel Ángel Saavedra Salinas,
  • Margarita Portela Hernández,
  • Hilda Fragoso Loyo,
  • Luis H. Silveira,
  • Ignacio García de la Torre,
  • Carlos Abud Mendoza,
  • Jorge A. Esquivel Valerio,
  • Isabel Acosta Colman,
  • Claudia Selene Mora Trujillo,
  • Katiuzka Zuñiga Corrales,
  • Roberto Muñoz Louis,
  • Martin Rebella,
  • Vicente Juarez,
  • Carlos Enrique Toro-Gutiérrez,
  • Ana Malvar,
  • Yurilis Fuentes,
  • Alain Cornet,
  • Laurent Arnaud,
  • Bernardo Pons-Estel,
  • Guillermo Pons-Estel

摘要

Objective

To assess the burden of systemic lupus erythematosus (SLE) from the perspective of patients in Latin America (LATAM) in 2024.

Methods

During May 2024, as part of International SLE Awareness Day, the Grupo Latinoamericano de Estudio del Lupus (GLADEL) disseminated an anonymous, bilingual (Spanish/Portuguese) online survey to patients with SLE. The survey, developed by Lupus Europe, was distributed through physicians and patient associations across LATAM and explored sociodemographic characteristics, disease features, treatments, and the impact on daily life.

Results

A total of 1991 responses from 21 Latin American countries were analyzed (Argentina, Brazil, the Dominican Republic, Chile, and Peru contributing the highest numbers). Most respondents were women (95.2%), with a mean age of 38.6 years (SD 11.6). Overall, 52.1% were married or partnered, 34.0% had completed secondary/vocational education, and 38.8% were employed. Regarding ethnicity, 25.5% identified as Caucasian and 34.4% as Mestizo. A prior alternative diagnosis was reported by 59.7%, with a mean age at diagnosis of 28.8 years (SD 10.6) and a median delay of 1 year (IQR 0–2). The most frequently affected organs were joints (71.4%), skin (47.4%), and kidneys (37.5%). Emotional and sexual life were negatively affected in 43.2%, and 62.1% reported impacts on education or career. Anxiety and/or depression were reported by 60%. Antimalarials, corticosteroids, immunosuppressives, and biologics were used by 80.9%, 55.7%, 59.9%, and 11.1%, respectively. Notably, 67.7% perceived their disease as under control.

Conclusion

Understanding patient perspectives is essential to evaluate the burden of SLE, and incorporating patient-reported experiences into decision-making should be prioritized.

Key Points

• Nearly 60% of patients experienced a misdiagnosis, with a median 1-year diagnostic delay.

• High psychosocial burden, including education/career disruption and anxiety/depression.High psychosocial burden, including education/career disruption and anxiety/depression.

• Conventional therapies are widely used; biologics remain underutilized.

• Two-thirds of patients perceived their disease as controlled.